Loading clinical trials...

TDM-optimized Teicoplanin Dosing Versus Standard of Care | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE4

TDM-optimized Teicoplanin Dosing Versus Standard of Care

A Randomized Trial Investigating the Superiority of TDM-optimized Teicoplanin Dosing Versus Standard of Care

NCT05914467•Radboud University Medical Center

Summary

Value of TDM for teicoplanin is not well defined. In this single-center low-interventional randomized trial the investigators aim to investigate the superiority of teicoplanin TDM-optimized using Model-Informed-Precision-Dosing (MIPD) of unbound concentrations versus the standard of care (dosing based on antibiotic guidelines) in target attainment.

Detailed Description

Teicoplanin is a glycopeptide antibiotic that is frequently used in the treatment of gram-positive bacterial infections. The glycopeptide antibiotic vancomycin is currently the first choice of treatment against methicillin-resistant Staphylococcus aureus (MRSA), but teicoplanin is found to have a similar efficacy while showing less nephrotoxicity (4.8% vs 10.7%). Vancomycin dosing is based on therapeutic drug monitoring (TDM). In contrast to vancomycin, value of TDM for teicoplanin is not as well defined. In this study the superiority of teicoplanin TDM-optimized dosing using Model-Informed-Precision-Dosing (MIPD) of unbound concentrations versus the standard of care (dosing based on antibiotic guidelines) in target attainment will be investigated. The overall aim of this research is to improve antibiotic treatment with teicoplanin to allow safe and optimal treatment of glycopeptide susceptible strains and to prevent de novo development of resistance.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The patient is admitted to the ICU, haematology, gastroenterology or orthopaedics department.
•2. The patient is at least 18 years old on the day of inclusion.
•3. The patient is treated with teicoplanin as part of standard care.
•4. The patient or a representative is willing to sign the Informed Consent Form

Exclusion Criteria

•1. The patient has previously participated in this study.
•2. The patient receives any form of renal replacement criteria (RRT) other than CVVHD / CVVHDF.
•3. Expected duration of teicoplanin therapy is less than 5 days.
•4. The patient is pregnant

Locations (1)

RadboudUMC

Nijmegen, Netherlands

Key Dates

Start Date

August 1, 2023

Primary Completion Date

April 30, 2026

Completion Date

April 30, 2026

Last Updated

February 18, 2026

Enrollment

ESTIMATED participants

Conditions

Bacterial Infections

Interventions

Teicoplanin

DRUG

[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

NCT04263792

Bacterial Infections

View study

RECRUITINGPHASE2

Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

NCT06135350

Gram Negative PneumoniaGram-Negative Bacterial Infections+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TDM-optimized Teicoplanin Dosing Versus Standard of Care

Inclusion Criteria

Exclusion Criteria

[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

Use of Low-cost Molecular Diagnostic Techniques as a New Surveillance Model for Diseases Preventable by Vaccinations.

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants